[1] Jilani SM, Frey MT, Pepin D, et al. Evaluation of State-Mandated Reporting of Neonatal Abstinence Syndrome — Six States, 2013–2017. MMWR Morb Mortal Wkly Rep 2019;68:6–10. DOI: http://dx.doi.org/10.15585/mmwr.mm6801a2
[2] Winkelman, Tyler NA, Nicole Villapiano, Katy B Kozhimannil, Matthew M Davis, and Stephen W Patrick. “Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004–2014.” Pediatrics 141, no. 4 (April 2018). https://pediatrics.aappublications.org/content/141/4/e20173520.
[3] Corr, Tammy E., and Christopher S. Hollenbeak. “The Economic Burden of Neonatal Abstinence Syndrome in the United States.” Addiction 112, no. 9 (June 13, 2017): 1590–99. https://doi.org/10.1111/add.13842.
[4] Corwin Rhyan, “The Potential Societal Benefit of Eliminating Opioid Overdoses, Deaths, and Substance Use Disorders Exceeds $95 Billion Per Year,” Center for Value in Health Care, November 2017, https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf
[5] Substance Abuse and Mental Health Services Administration. Projections of National Expenditures for Treatment of Mental and Substance Use Disorders, 2010–2020.pg 41. HHS Publication No. SMA-14-4883. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. https://store.samhsa.gov/system/files/sma14-4883.pdf
[6] Davida Schiff et al., “Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts,” Obstetrics & Gynecology 132, no. 2 (August 2018): 466-474, https://doi.org/10.1097/AOG.0000000000002734
[7] Normile, Becky, Carrie Hanlon, and Hannah Eichner. “State Options for Promoting Recovery among Pregnant and Parenting Women with Opioid or Substance Use Disorder.” National Academy for State Health Policy, October 30, 2018. https://www.oldsite.nashp.org/wp-content/uploads/2018/10/NOSLO-Opioids-and-Women-Final.pdf.
[8] Normile, Becky, Carrie Hanlon, and Hannah Eichner. “State Options for Promoting Recovery among Pregnant and Parenting Women with Opioid or Substance Use Disorder.” National Academy for State Health Policy, October 30, 2018. https://www.oldsite.nashp.org/wp-content/uploads/2018/10/NOSLO-Opioids-and-Women-Final.pdf.
[9] “Quality of Care Measures.” Health Center Data. Health Services Resource Administration. Accessed November 1, 2019. https://bphc.hrsa.gov/uds/datacenter.aspx?q=t6b&year=2018&state=.
[10] Opioid Use and Opioid Use Disorder in Pregnancy.” ACOG Committee Opinion, no. 711 (August 2017). https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-in-Pregnancy.
[11] Opioid Use and Opioid Use Disorder in Pregnancy.” ACOG Committee Opinion, no. 711 (August 2017). https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-in-Pregnancy.
[12] Wright, T.E., Terplan, M., Ondersma, S.J., Boyce, C., Yonkers, K., et al. (2016). The role of screening, brief intervention, and referral to treatment in the perinatal period. American Journal of Obstetrics & Gynecology, 215(5), 539-547.
[13] “Mental Health and Substance Abuse Health Coverage Options.” HealthCare.gov. Accessed October 16, 2019. https://www.healthcare.gov/coverage/mental-health-substance-abuse-coverage/.
[14] Gifford, Kathy, Jenna Walls, Usha Ranji, Alina Salganicoff, and Ivette Gomez. “Medicaid Coverage of Pregnancy and Perinatal Benefits: Results from a State Survey.” The Henry J. Kaiser Family Foundation, June 19, 2019. https://www.kff.org/womens-health-policy/report/medicaid-coverage-of-pregnancy-and-perinatal-benefits-results-from-a-state-survey/.
[15] Walden, and Greg. “H.R.6 – 115th Congress (2017-2018): SUPPORT for Patients and Communities Act.” Congress.gov, October 24, 2018. https://www.congress.gov/bill/115th-congress/house-bill/6.
[16] Published: Jun 03, 2019. “Medicaid’s Role in Addressing the Opioid Epidemic.” The Henry J. Kaiser Family Foundation, July 15, 2019. https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/
[17] National Institute on Drug Abuse. “Treating Opioid Use Disorder During Pregnancy.” NIDA, July 2017. https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy.
[18] “Substance Use Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act: Section 1003.” Medicaid.gov. Accessed October 16, 2019. https://www.medicaid.gov/medicaid/benefits/bhs/support-act-provider-capacity-demos/index.html.
[19] Cash, Judith. Strategies to Address the Opioid Epidemic, Strategies to Address the Opioid Epidemic § (2017). https://www.medicaid.gov/federal-policy-guidance/downloads/smd17003.pdf
[20] “Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State.” The Henry J. Kaiser Family Foundation, October 9, 2019. https://www.kff.org/medicaid/issue-brief/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state/.
[21] “TennCare’s Opioid Strategy.” Tennessee State Government – TN.gov. Accessed October 17, 2019. https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html.
[22] Obstetric Pay for Performance Program, Obstetric Pay for Performance Program § (2014). https://www.huskyhealthct.org/providers/provider_postings/Obstetric_Pay_for_Performance_Program.pdf.
[23] Obstetric Pay for Performance Program, Obstetric Pay for Performance Program § (2019). https://www.huskyhealthct.org/providers/provider_postings/OBP4P_PayForPerformance.pdf
[24] Obstetric Pay for Performance Program, Obstetric Pay for Performance Program § (2019). https://www.huskyhealthct.org/providers/provider_postings/OBP4P_PayForPerformance.pdf
[25] Statewide Medicaid Managed Care Quality Initiatives Public Meeting, Statewide Medicaid Managed Care Quality Initiatives Public Meeting § (2019). https://ahca.myflorida.com/Medicaid/Policy_and_Quality/Quality/QI-initiatives/Stakeholder_Meeting_Presentation_FINAL012519_v1_Shared.pdf.
[26] Section 1115(a) Demonstration Amendment Request to CMS – Draft for Public Notice 12/14/2017, Section 1115(a) Demonstration Amendment Request to CMS – Draft for Public Notice 12/14/2017 § (2017). https://dvha.vermont.gov/global-commitment-to-health/vt-gc-1115-waiver-sud-amendment-draft-for-public-notice.pdf.
[27] Section 1115(a) Demonstration Amendment Request to CMS – Draft for Public Notice 12/14/2017, Section 1115(a) Demonstration Amendment Request to CMS – Draft for Public Notice 12/14/2017 § (2017). https://dvha.vermont.gov/global-commitment-to-health/vt-gc-1115-waiver-sud-amendment-draft-for-public-notice.pdf.
[28] “Florida Perinatal Quality Collaborative.” Florida Perinatal Quality Collaborative | USF Health. Accessed October 17, 2019. https://health.usf.edu/publichealth/chiles/fpqc.
[29] “The Meadowlark Initiative.” Montana Healthcare Foundation – Helping to change the lives of people across Montana through innovative healthcare services. Accessed October 17, 2019. https://mthcf.org/the-meadowlark-initiative/.